NDATOPICALCREAM
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
LUZU (luliconazole) by Bausch + Lomb is cytochrome p450 2c19 inhibitors [moa]. Approved for azole antifungal [epc]. First approved in 2013.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUZU (luliconazole) is a topical azole antifungal cream approved in 2013 for treating fungal infections of the skin. It works by inhibiting fungal cytochrome P450 2C19, disrupting ergosterol synthesis and fungal cell membrane integrity. The product is currently in peak lifecycle phase with strong patent protection extending to 2034.
$0.018MPart D
Peak7.9 years to LOELow Part D penetration suggests limited market adoption relative to competitors; brand teams managing stable but niche patient base.
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Started Feb 2016
75 enrolled
Tinea Corporis
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Started Dec 2015
30 enrolled
Tinea PedisTinea Cruris
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Started Feb 2015
20 enrolled
Tinea PedisTinea Cruris
Career Relevance
LUZU positions candidates for commercial and market access roles in a mature, competitive specialty dermatology portfolio. The product's low Part D penetration and stable-but-limited market profile offer hands-on experience in defending market share against branded competitors rather than driving growth, emphasizing account management and formulary strategy skills.
Worked on LUZU at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.